BSYI
Biosyntech Inc
Price:  
0.00 
USD
Volume:  
21,000.00
Canada | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

BSYI WACC - Weighted Average Cost of Capital

The WACC of Biosyntech Inc (BSYI) is 7.9%.

The Cost of Equity of Biosyntech Inc (BSYI) is 60,175.70%.
The Cost of Debt of Biosyntech Inc (BSYI) is 9.75%.

Range Selected
Cost of equity 10,788.80% - 109,562.60% 60,175.70%
Tax rate 26.20% - 27.00% 26.60%
Cost of debt 7.00% - 12.50% 9.75%
WACC 5.3% - 10.6% 7.9%
WACC

BSYI WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 2344.56 19563.88
Additional risk adjustments 0.0% 0.5%
Cost of equity 10,788.80% 109,562.60%
Tax rate 26.20% 27.00%
Debt/Equity ratio 74441.83 74441.83
Cost of debt 7.00% 12.50%
After-tax WACC 5.3% 10.6%
Selected WACC 7.9%

BSYI's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for BSYI:

cost_of_equity (60,175.70%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (2344.56) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.